Eledon Pharmaceuticals, Inc.: Form 10-Q for the period ended Mar 31, 2018
Filed with the SEC on May 11, 2018 and accepted by EDGAR at May 10, 2018, 19:19 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2018-01-01 to 2018-03-31 | $1.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-01-01 to 2018-03-31 | −$2.8m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2018-01-01 to 2018-03-31 | −$2.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-01-01 to 2018-03-31 | −$0.36 | us-gaap:EarningsPerShareBasicAndDiluted |
| Cash and equivalents | At period end2018-03-31 | $22.5m | us-gaap:Cash |
| Current assets | At period end2018-03-31 | $24.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-03-31 | $25.9m | us-gaap:Assets |
| Total liabilities | At period end2018-03-31 | $1.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-03-31 | $24.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-18-013090. Last ingested by Listed: Nov 13, 2026, 16:16 ET. Listed shows no prices and gives no investment advice.